Single-agent chemotherapy

DRUG2 trials

Sponsors

Fondazione Ricerca Traslazionale, Replimune, Inc.

Conditions

Advanced MelanomaNon-small-cell Lung Cancer Patients

Phase 2

Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab

RecruitingNCT05568212

Fondazione Ricerca TraslazionaleNon-small-cell Lung Cancer Patients

Start: 2022-05-02End: 2027-05-31Target: 176Updated: 2025-12-01

Phase 3

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

RecruitingNCT06264180

Replimune, Inc.Advanced Melanoma

Start: 2024-07-11End: 2034-08-31Target: 400Updated: 2026-05-15

Related Papers

A randomized, controlled, multicenter, phase 3 study of vusolimogene oderparepvec combined with nivolumab vs treatment of physician’s choice in patients with advanced melanoma that has progressed on anti–PD-1 and anti–CTLA-4 therapy (IGNYTE-3).

Journal of Clinical Oncology2025-05-28

A randomized, controlled, multicenter, phase 3 study of vusolimogene oderparepvec (VO) combined with nivolumab vs treatment of physician’s choice in patients with advanced melanoma that has progressed on anti–PD-1 and anti–CTLA-4 therapy (IGNYTE-3).

Journal of Clinical Oncology2024-06-016 citations